Fundraising FoxYsios Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Co-investorsAndera PartnersCatalys PacificHBM Healthcare InvestmentsHBM PartnersSamsara BioCapitalSR One Capital Management+3 more
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture Fund+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.